Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

Science Translational Medicine

Volumn 5, Issue 179, 2013, Pages

  Matsuoka, Ken Ichi ^a,b   Koreth, John ^a,b   Kim, Haesook T ^a,c   Bascug, Gregory ^a   McDonough, Sean ^a   Kawano, Yutaka ^a,b   Murase, Kazuyuki ^a,b   Cutler, Corey ^a,b   Ho, Vincent T ^a,b   Alyea, Edwin P ^a,b   Armand, Philippe ^a,b   Blazar, Bruce R ^d   Antin, Joseph H ^a,b   Soiffer, Robert J ^a,b   Ritz, Jerome ^a,b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 7; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; STAT5 PROTEIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ADULT; APOPTOSIS; CELL PROLIFERATION; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HOMEOSTASIS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84876012054     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005265     Document Type: Article

References (47)

1. S. Bhatia, L. Francisco, A. Carter, C. L. Sun, K. S. Baker, J. G. Gurney, P. B. McGlave, A. Nademanee, M. O'Donnell, N. K. Ramsay, L. L. Robison, D. Snyder, A. Stein, S. J. Forman, D. J. Weisdorf, Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study. Blood 110, 3784-3792 (2007).
2. T. A. Gooley, J.W. Chien, S. A. Pergam, S. Hingorani, M. L. Sorror, M. Boeckh, P. J.Martin, B. M. Sandmaier, K. A. Marr, F. R. Appelbaum, R. Storb, G. B. McDonald, Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363, 2091-2101 (2010).
3. J. Pidala, C. Anasetti, H. Jim, Quality of life after allogeneic hematopoietic cell transplantation. Blood 114, 7-19 (2009).
4. V. Ratanatharathorn, L. Ayash, H. M. Lazarus, J. Fu, J. P. Uberti, Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant. 28, 121-129 (2001).
5. S. J. Lee, G. Vogelsang, M. E. Flowers, Chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 9, 215-233 (2003).
6. S. Arai, M. Jagasia, B. Storer, X. Chai, J. Pidala, C. Cutler, M. Arora, D. J. Weisdorf, M. E. Flowers, P. J. Martin, J. Palmer, D. Jacobsohn, S. Z. Pavletic, G. B. Vogelsang, S. J. Lee, Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 118, 4242-4249 (2011).
7. D. B. Miklos, H. T. Kim, K. H. Miller, L. Guo, E. Zorn, S. J. Lee, E. P.Hochberg, C. J. Wu, E. P. Alyea, C. Cutler, V. Ho, R. J. Soiffer, J. H. Antin, J. Ritz, Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105, 2973-2978 (2005).
8. S. Sarantopoulos, K. E. Stevenson, H. T. Kim, C. S. Cutler, N. S. Bhuiya, M. Schowalter, V. T. Ho, E. P. Alyea, J. Koreth, B. R. Blazar, R. J. Soiffer, J. H. Antin, J. Ritz, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113, 3865-3874 (2009).
9. M. Srinivasan, R. Flynn, A. Price, A. Ranger, J. L. Browning, P. A. Taylor, J. Ritz, J. H. Antin, W. J. Murphy, L. Luznik, M. J. Shlomchik, A. Panoskaltsis-Mortari, B. R. Blazar, Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119, 1570-1580 (2012).
10. K. Wing, S. Sakaguchi, Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7-13 (2010).
11. E. Zorn, H. T. Kim, S. J. Lee, B. H. Floyd, D. Litsa, S. Arumugarajah, R. Bellucci, E. P. Alyea, J. H. Antin, R. J. Soiffer, J. Ritz, Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106, 2903-2911 (2005).
12. Q. Tang, J. A. Bluestone, The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat. Immunol. 9, 239-244 (2008).
13. K. Rieger, C. Loddenkemper, J. Maul, T. Fietz, D. Wolff, H. Terpe, B. Steiner, E. Berg, S. Miehlke, M. Bornhäuser, T. Schneider, M. Zeitz, H. Stein, E. Thiel, R. Duchmann, L. Uharek, Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107, 1717-1723 (2006).
14. K. Matsuoka, H. T. Kim, S. McDonough, G. Bascug, B. Warshauer, J. Koreth, C. Cutler, V. T. Ho, E. P. Alyea, J. H. Antin, R. J. Soiffer, J. Ritz, Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 120, 1479-1493 (2010).
15. S. Thiant, I. Yakoub-Agha, L. Magro, J. Trauet, V. Coiteux, J. P. Jouet, J. P. Dessaint, M. Labalette, Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant. 45, 1546-1552 (2010).
16. S. Thiant, M. Labalette, J. Trauet, V. Coiteux, E. de Berranger, J. P. Dessaint, I. Yakoub-Agha, Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 46, 1374-1381 (2011).
17. R. M. Dean, T. Fry, C. Mackall, S. M. Steinberg, F. Hakim, D. Fowler, J. Odom, J. Foley, R. Gress, M. R. Bishop, Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J. Clin. Oncol. 26, 5735-5741 (2008).
18. R. Mazzucchelli, S. K. Durum, Interleukin-7 receptor expression: Intelligent design. Nat. Rev. Immunol. 7, 144-154 (2007).
19. C. Sportès, R. R. Babb, M. C. Krumlauf, F. T. Hakim, S. M. Steinberg, C. K. Chow, M. R. Brown, T. A. Fleisher, P. Noel, I. Maric, M. Stetler-Stevenson, J. Engel, R. Buffet, M. Morre, R. J. Amato, A. Pecora, C. L. Mackall, R. E. Gress, Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 16, 727-735 (2010).
20. C. Sportès, F. T. Hakim, S. A. Memon, H. Zhang, K. S. Chua, M. R. Brown, T. A. Fleisher, M. C. Krumlauf, R. R. Babb, C. K. Chow, T. J. Fry, J. Engels, R. Buffet, M. Morre, R. J. Amato, D. J. Venzon, R. Korngold, A. Pecora, R. E. Gress, C. L. Mackall, Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 205, 1701-1714 (2008).
21. M. C. Sneller, W. C. Kopp, K. J. Engelke, J. L. Yovandich, S. P. Creekmore, T. A. Waldmann, H. C. Lane, IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood 118, 6845-6848 (2011).
22. M. A. Perales, J. D. Goldberg, J. Yuan, G. Koehne, L. Lechner, E. B. Papadopoulos, J. W. Young, A. A. Jakubowski, B. Zaidi, H. Gallardo, C. Liu, T. Rasalan, J. D. Wolchok, T. Croughs, M. Morre, S. M. Devlin, M. R. van den Brink, Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 120, 4882-4891 (2012).
23. O. Boyman, J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180-190 (2012).
24. A. Yu, T. R. Malek, Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells. J. Immunol. 177, 5115-5121 (2006).
25. L. Barron, H. Dooms, K. K. Hoyer, W. Kuswanto, J. Hofmann, W. E. O'Gorman, A. K. Abbas, Cutting edge: Mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J. Immunol. 185, 6426-6430 (2010).
26. Z. Popmihajlov, K. A. Smith, Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity. PLoS One 3, e1581 (2008).
27. K. E. Webster, S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey, J. Sprent, In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751-760 (2009).
28. J. Y. Humrich, H. Morbach, R. Undeutsch, P. Enghard, S. Rosenberger, O. Weigert, L. Kloke, J. Heimann, T. Gaber, S. Brandenburg, A. Scheffold, J. Huehn, A. Radbruch, G. R. Burmester, G. Riemekasten, Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. U.S.A. 107, 204-209 (2010).
29. R. Setoguchi, S. Hori, T. Takahashi, S. Sakaguchi, Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005).
30. Q. Tang, J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, J. A. Bluestone, Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
31. E. Zorn, E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, D. A. Frank, J. Ritz, IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108, 1571-1579 (2006).
32. D. Saadoun, M. Rosenzwajg, F. Joly, A. Six, F. Carrat, V. Thibault, D. Sene, P. Cacoub, D. Klatzmann, Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067-2077 (2011).
33. J. Koreth, K. Matsuoka, H. T. Kim, S. M. McDonough, B. Bindra, E. P. Alyea III, P. Armand, C. Cutler, V. T. Ho, N. S. Treister, D. C. Bienfang, S. Prasad, D. Tzachanis, R. M. Joyce, D. E. Avigan, J. H. Antin, J. Ritz, R. J. Soiffer, Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066 (2011).
34. Y. Rochman, R. Spolski, W. J. Leonard, New insights into the regulation of T cells by gc family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
35. Y. P. Rubtsov, R. E. Niec, S. Josefowicz, L. Li, J. Darce, D. Mathis, C. Benoist, A. Y. Rudensky, Stability of the regulatory T cell lineage in vivo. Science 329, 1667-1671 (2010).
36. S. Z. Josefowicz, A. Rudensky, Control of regulatory T cell lineage commitment and maintenance. Immunity 30, 616-625 (2009).
37. S. Junge, B. Kloeckener-Gruissem, R. Zufferey, A. Keisker, B. Salgo, J. C. Fauchere, F. Scherer, T. Shalaby, M. Grotzer, U. Siler, R. Seger, T. Güngör, Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur. J. Immunol. 37, 3270-3280 (2007).
38. S. Kohler, A. Thiel, Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood 113, 769-774 (2009).
39. O. Boyman, J. F. Purton, C. D. Surh, J. Sprent, Cytokines and T-cell homeostasis. Curr. Opin. Immunol. 19, 320-326 (2007).
40. Y. Sawa, Y. Arima, H. Ogura, C. Kitabayashi, J. J. Jiang, T. Fukushima, D. Kamimura, T. Hirano, M. Murakami, Hepatic interleukin-7 expression regulates T cell responses. Immunity 30, 447-457 (2009).
41. D. J. Stauber, E. W. Debler, P. A. Horton, K. A. Smith, I. A. Wilson, Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 2788-2793 (2006).
42. X. Wang, M. Rickert, K. C. Garcia, Structure of the quaternary complex of interleukin-2 with its a, b, and gc receptors. Science 310, 1159-1163 (2005).
43. T. Nakarai, M. J. Robertson, M. Streuli, Z. Wu, T. L. Ciardelli, K. A. Smith, J. Ritz, Interleukin 2 receptor g chain expression on resting and activated lymphoid cells. J. Exp. Med. 180, 241-251 (1994).
44. A. J. Grant, E. Roessler, G. Ju, M. Tsudo, K. Sugamura, T. A. Waldmann, The interleukin 2 receptor (IL-2R): The IL-2R a subunit alters the function of the IL-2R b subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R a subunit. Proc. Natl. Acad. Sci. U.S.A. 89, 2165-2169 (1992).
45. M. Tsudo, F. Kitamura, M. Miyasaka, Characterization of the interleukin 2 receptor b chain using three distinct monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 86, 1982-1986 (1989).
46. S. Yokoyama, N. Watanabe, N. Sato, P. Y. Perera, L. Filkoski, T. Tanaka, M. Miyasaka, T. A. Waldmann, T. Hiroi, L. P. Perera, Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc. Natl. Acad. Sci. U.S.A. 106, 15849-15854 (2009).
47. S. A. Hartgring, C. R. Willis, D. Alcorn, L. J. Nelson, J. W. Bijlsma, F. P. Lafeber, J. A. van Roon, Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 62, 2716-2725 (2010).